Pfizer receives positive CHMP opinion for Vizimpro® (dacomitinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR-activating mutations
- Details
- Category: Pfizer
Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Vizimpro® (dacomitinib) 45 mg, as monotherapy, be granted marketing authorization in the European Union (EU) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.
Merck Granted U.S. Patent for novel combination of Artificial Intelligence and Blockchain Technology
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced that it has been granted Patent No. US 10,193,695 by the United States Patent and Trademark Office (USPTO). The patent relates to the formation of 'crypto-objects', a novel security procedure linking Artificial Intelligence (AI) and blockchain technology.
Pfizer and Lilly announce top-line results from second Phase 3 study of tanezumab in osteoarthritis pain
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis (OA) pain. The tanezumab 5 mg treatment arm met all three co-primary endpoints at 24 weeks, demonstrating a statistically significant improvement in pain, physical function and the patients' overall assessment of their OA compared to those receiving placebo.
Amgen receives NMPA approval for Repatha® (evolocumab) In China to reduce the risk of cardiovascular events
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) announced that the National Medical Products Administration (NMPA) has approved a new indication for Repatha® (evolocumab) as the first PCSK9 inhibitor in China for adults with established atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of myocardial infarction, stroke and coronary revascularization.
Merck and Tencent announce collaboration on intelligent digital healthcare services in China
- Details
- Category: Merck Group
Merck, a leading science and technology company, signed a strategic collaboration agreement with Tencent, a leading provider of Internet value added services. The collaboration will primarily focus on increasing public disease awareness and providing more accessible healthcare services via digital platforms in China, by leveraging the company's scientific leadership and expertise combined with Tencent's leading technology in the fields of internet and artificial intelligence.
A healthy 2019: Four paws for more relaxation and exercise
- Details
- Category: Boehringer Ingelheim
Pets spend their whole lives at their owners' sides, keeping them active and comforting them in times of illness or loneliness. A study conducted by research organization IPSOS on behalf of Boehringer Ingelheim recently confirmed what many pet owners have long suspected: Dogs, cats and other pets have a positive impact on health and well-being.
FDA accepts Roche's supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin)
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) in combination with Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) and carboplatin for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations.
More Pharma News ...
- Amgen and UCB receive positive vote from FDA Advisory Committee in favor of approval for EVENITY™ (romosozumab)
- Merck welcomes ten new startups to its Innovation Center
- Abbott to acquire Cephea Valve Technologies, Inc.
- European Commission approves Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) for first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma
- US FDA accepts regulatory submissions for review of tafamidis to treat transthyretin amyloid cardiomyopathy
- EVENITY™ (romosozumab) receives approval in Japan for the treatment of osteoporosis in patients at high risk of fracture
- Boehringer Ingelheim initiates a collaborative partnership with Science 37 to accelerate patient centricity in the development of novel therapies